Health on MSN
What's the life expectancy for complement 3 glomerulopathy—and how does it affect quality of life?
Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the ...
Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms such as swelling and changes in urine ...
Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...
The authors report a case of deficiency of the eighth component of complement in a young adult with a history of three episodes of meningitis; one of them proved to be meningococcal. The literature ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
Early erythrolysis occurs within the hematoma following intracerebral hemorrhage (ICH), and the release of erythrocyte cytoplasmic proteins such as hemoglobin and Prx2 (peroxiredoxin 2) can cause ...
What Is Empaveli, and Why Does It Matter? First approved in 2021 for a rare blood disorder, Empaveli (pegcetacoplan) is now approved as the first targeted medicine for adults and children aged 12 ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
- Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 PASADENA, ...
(RTTNews) - Arrowhead Pharmaceuticals, Inc. (ARWR) Monday announced positive topline results from Part 2 of a Phase 1/2 study of ARO-C3 in patients with IgA nephropathy (IgAN). ARO-C3 is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results